Biohaven Therapeutics Ltd.

Quick facts

Phase 3 pipeline

• BHV-4157 · Neurology
  BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine.

Phase 2 pipeline

• BHV-2100 · Neurology
  BHV-2100 is a calcitonin gene-related peptide receptor antagonist.
• BHV-7000 · Neurology
  BHV-7000 is a calcitonin gene-related peptide receptor antagonist.
• BHV-8000 · Neurology
  BHV-8000 is a calcitonin gene-related peptide receptor antagonist.

Phase 1 pipeline

• BHV-1300
• BHV-1400
• BHV-1510
• BHV-1530

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biohaven Therapeutics Ltd. portfolio CI brief
• Biohaven Therapeutics Ltd. pipeline updates RSS